Moreover, in the KCSG-HB19-19 trial, trastuzumab with FLOFOX regimen (leucovorin, 5-FU, and oxaliplatin) illustrated a favorable disease control rate of 79.4%, however, a lower ORR: 29.4% in 34 patients with HER2-positive CCA (IHC3+ or 2+ with ISH amplification) [177]. This evidence concerns the gene ERBB2 and cholangiocarcinoma.